Blueprint Medicines Corp (BPMC)
94.15
-2.47
(-2.56%)
USD |
NASDAQ |
Nov 22, 16:00
94.20
+0.05
(+0.05%)
After-Hours: 20:00
Blueprint Medicines Gross Profit Margin (Quarterly): 98.49% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 98.49% |
| June 30, 2024 | 94.50% |
| March 31, 2024 | 96.68% |
| December 31, 2023 | 99.64% |
| September 30, 2023 | 95.08% |
| June 30, 2023 | 95.96% |
| March 31, 2023 | 94.98% |
| December 31, 2022 | 87.50% |
| September 30, 2022 | 95.45% |
| June 30, 2022 | 86.63% |
| Date | Value |
|---|---|
| March 31, 2022 | 91.90% |
| December 31, 2021 | 92.95% |
| September 30, 2021 | 84.33% |
| June 30, 2021 | 76.21% |
| March 31, 2021 | 99.53% |
| December 31, 2020 | 99.62% |
| September 30, 2020 | 99.98% |
| June 30, 2020 | 98.48% |
| March 31, 2020 | 99.61% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
76.21%
Minimum
Jun 2021
99.98%
Maximum
Sep 2020
94.08%
Average
95.45%
Median
Sep 2022
Gross Profit Margin (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 74.73% |
| Regeneron Pharmaceuticals Inc | 86.80% |
| NovaBay Pharmaceuticals Inc | 65.26% |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -50.13% |
| Return on Assets | -11.44% |
| Return on Invested Capital | -23.14% |
| Profit Margin (Quarterly) | -43.90% |
| Operating Margin (Quarterly) | -38.21% |
| Return on Net Operating Assets | -67.45% |